Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769823 | 0.87 | PTPN1 (0.46) | PTPN1CXCR2KDM4E | |
| SCHEMBL6315778 | 0.81 | PTPN2 (0.38) | PTPN1CXCR2ALDH1A1HPGDKDM4E | |
| SCHEMBL5837646 | 0.80 | HPGD (0.42) | PTPN1CXCR2ALDH1A1HTTHPGD | |
| SCHEMBL5768909 | 0.79 | PTPN1 (0.62) | PTPN1 | |
| SCHEMBL5769066 | 0.77 | PTPN1 (0.39) | PTPN1CXCR2ALDH1A1MAPK1 | |
| SCHEMBL5772238 | 0.72 | NT5E (0.39) | PTPN1CXCR2ALDH1A1HPGDKDM4E | |
| SCHEMBL5837475 | 0.72 | PTPN1 (0.40) | PTPN1CXCR2ALDH1A1USP2MAPK1 | |
| SCHEMBL5838593 | 0.71 | PTPN2 (0.39) | PTPN1CXCR2ALDH1A1USP2MAPK1 | |
| SCHEMBL5837100 | 0.70 | CXCR2 (0.36) | PTPN1CXCR2ALDH1A1HPGD | |
| SCHEMBL5837700 | 0.67 | PTPN2 (0.41) | PTPN1CXCR2ALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301516-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-6613903-B2 | Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | PTPRO, PTPN1, PTPRS | PTPN1 2/4885CXCR2 617/4885ALDH1A1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.